← All Silence Therapeutics PLC filings

Silence Therapeutics PLC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
SLN
Silence Therapeutics PLC
10-K: Silence Therapeutics Reports $88.6M Loss, AstraZeneca Exits SLN312
Silence Therapeutics reported a significant net loss of $88.6 million for 2025, alongside AstraZeneca's decision to discontinue further development of SLN312 beyond Phase 1.
NASDAQ
SLN
Silence Therapeutics PLC
10-K/A: Silence Therapeutics Amends 10-K to Include Part III Information and Updated Exhibits
Silence Therapeutics files an amendment to its 2024 Annual Report on Form 10-K to include previously omitted information regarding directors, executive compensation, security ownership, related transactions, and principal accountant fees.
NASDAQ
SLN
Silence Therapeutics PLC
10-K: Silence Therapeutics Reports Full Year 2024 Results, Highlights Progress in Clinical Programs and Phase 3 Readiness
Silence Therapeutics reports its full year 2024 results, showcasing advancements in its clinical programs and preparations for Phase 3 trials.